TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11139111

Group type: EXPERIMENTAL
Intervention: BIS value of 60
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BIS value of 50
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BIS value of 40
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (BIS values 60 and 50)
Number of subjects: 45
Study: 9379067

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with background opioid infusion
Number of subjects: 6000
Study: 8269563

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 28
Study: 2863392

Group type: EXPERIMENTAL
Intervention: 10 mg. dezocine
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 15 mg. dezocine
Number of subjects: 149

Group type: COMPARATOR
Intervention: 10 mg. morphine
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both groups (dezocine and morphine)
Number of subjects: 149
Study: 31295275

Group type: EXPERIMENTAL
Intervention: BLS education with web-based education in cardiovascular diseases (CVD)
Number of subjects: 2623

Group type: COMPARATOR
Intervention: BLS education without web-based education in CVD
Number of subjects: 2623
Study: 29176383

Group type: EXPERIMENTAL
Intervention: Jump Interval Training (JIT) - performed twice per week, consisting of 4-6 bouts of continuous vertical jumping (30 seconds) with 5-minute intervals
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous endurance training (40-minute running at 70% of peak aerobic velocity, 3 times per week for 4 weeks)
Number of subjects: 18
Study: 27279266

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 144
Study: 24485479

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg orally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22961867

Group type: EXPERIMENTAL
Intervention: Acute oral antioxidant cocktail (AOC) consisting of vitamin C, E, and α-lipoic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20591671

Group type: EXPERIMENTAL
Intervention: BPTB reconstruction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ST/G reconstruction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intact contralateral leg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 18093299

Group type: COMPARATOR
Intervention: Standard cryotherapy (intermittent ice applications with compression)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cryokinetic treatment (intermittent ice applications with compression and therapeutic exercise)
Number of subjects: 120
Study: 16128933

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study: 12150230

Group type: EXPERIMENTAL
Intervention: Self-disclosure and typicality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-disclosure and category salience
Number of subjects: 0
Study: 11155139

Group type: EXPERIMENTAL
Intervention: Systemic interferon‐alpha‐2A treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Prednisolone enemas
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low‐field magnetic resonance imaging
Number of subjects: 79
Study: 8788287

Group type: EXPERIMENTAL
Intervention: Whey-based formula
Number of subjects: 24
Study: 1319732

Group type: EXPERIMENTAL
Intervention: FUdR-C8 ester in Lipiodol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Water-soluble adriamycin emulsified in Lipiodol (control)
Number of subjects: 103
Study: 6711479

Group type: EXPERIMENTAL
Intervention: Hydrogenated fat diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonhydrogenated fat diet
Number of subjects: 8
Study: 31375102

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29111889

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing raspberry ketone, capsaicin, caffeine, garlic, and Citrus aurantium (EXP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dietary supplement (EXP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study: 26893135

Group type: EXPERIMENTAL
Intervention: 9-month pharmacist intervention
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 24-month pharmacist intervention
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 390
Study: 24694358

Group type: EXPERIMENTAL
Intervention: Vicco(®) turmeric cream (VTC) applied five times a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Johnson's(®) baby oil (Control) applied five times a day
Number of subjects: 50
Study: 22338101

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 110
Study: 20706632

Group type: EXPERIMENTAL
Intervention: Peptide vaccine (1 or 4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 17510493

Group type: EXPERIMENTAL
Intervention: L-lysine (2.64 g per day) and L-arginine (2.64 g per day)
Number of subjects: 108
Study: 15982133

Group type: EXPERIMENTAL
Intervention: Fixation distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral distractors
Number of subjects: 0
Study: 11918580

Group type: EXPERIMENTAL
Intervention: Natural vegetable fats (rape seed and palm fats)
Number of subjects: 20
Study: 10341866

Group type: COMPARATOR
Intervention: Carbimazole for 18 months
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Carbimazole for 42 months
Number of subjects: 134
Study: 7861489

Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy at 20 to 24 kv
Number of subjects: 82

Group type: COMPARATOR
Intervention: Gated lithotripsy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy with pharmacological manipulation
Number of subjects: 82
Study: 30375189

Group type: EXPERIMENTAL
Intervention: Adenosine-loaded DMN (Ad-DMN) patches and topical adenosine-loaded cream (Ad-cream)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Topical adenosine-loaded cream (Ad-cream)
Number of subjects: 21
Study: 28859944

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study: 25040544

Group type: EXPERIMENTAL
Intervention: Fluoride mouth rinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouth rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 36
Study: 24051108

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 986
Study: 21234793

Group type: EXPERIMENTAL
Intervention: Intervention group (n=30) participated in three weekly group sessions followed by three weekly follow-up telephone calls over six weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30) did not receive the intervention.
Number of subjects: 60
Study: 18300284

Group type: EXPERIMENTAL
Intervention: Phenserine (30 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Donepezil (5 mg/day)
Number of subjects: 20
Study: 15988805

Group type: EXPERIMENTAL
Intervention: Real-time quantitative PCR
Number of subjects: 54

Group type: COMPARATOR
Intervention: REP-PCR
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 54
Study: 12757352

Group type: EXPERIMENTAL
Intervention: Residential program based on the TEACCH model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEACCH methods
Number of subjects: 0
Study: 10391179

Group type: EXPERIMENTAL
Intervention: P‐IGIV 1500 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P‐IGIV 750 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P‐IGIV 250 mg/kg
Number of subjects: 30
Study: 9010611

Group type: EXPERIMENTAL
Intervention: Felodipine ER (2.5 mg)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Combination therapy (Felodipine ER 2.5 mg / Ramipril 2.5 mg)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 642

Group type: COMPARATOR
Intervention: Felodipine ER monotherapy
Number of subjects: 642

Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 642

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 642
Study: 2005326

Group type: EXPERIMENTAL
Intervention: Local immunotherapy (LIT) with Dermatophagoides extract
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6505647

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no indomethacin)
Number of subjects: 78
Study: 30475306

Group type: EXPERIMENTAL
Intervention: Personalized online tools and access to telephonic coaching sessions
Number of subjects: 175
Study: 29537658

Group type: EXPERIMENTAL
Intervention: Modified Sims position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Free position
Number of subjects: 120
Study: 26953637

Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based health coaching plus a written action plan for exacerbations and brief exercise advice
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based health coaching
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study: 23821246

Group type: EXPERIMENTAL
Intervention: Magnetic locking technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 80
Study: 23152865

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) and treatment instruction (TI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) and non-treatment instruction (NI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham acupuncture (SA) and treatment instruction (TI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham acupuncture (SA) and non-treatment instruction (NI)
Number of subjects: 41
Study: 20021994

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 63
Study: 18061171

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-binding protein-1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-binding protein-1 (ex vivo)
Number of subjects: 14

Group type: COMPARATOR
Intervention: PBS (ex vivo)
Number of subjects: 14
Study: 15983299

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 12 weeks followed by 45 mg once daily for an additional 12 weeks
Number of subjects: 802

Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg once daily followed by 4 mg twice daily for the same intervals
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 802

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 802
Study: 12464326

Group type: EXPERIMENTAL
Intervention: Haloperidol (dopamine D2-receptor antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study: 10603715

Group type: EXPERIMENTAL
Intervention: ELISA test for IgG and IgM using glycolipid PGL-I antigen from Mycobacterium leprae
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC) isolated by PEG 6000 precipitation method
Number of subjects: 122

Group type: COMPARATOR
Intervention: Comparison with tuberculosis patients
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CIC antibody levels during leprosy reactions
Number of subjects: 122
Study: 7860911

Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg twice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1781047

Group type: EXPERIMENTAL
Intervention: RT + TAM (tamoxifen) for one year
Number of subjects: 1664

Group type: COMPARATOR
Intervention: RT (no further therapy)
Number of subjects: 1664
Study: 6109587

Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of prazosin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30649458

Group type: EXPERIMENTAL
Intervention: 50 mg of tapentadol
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 mg of tramadol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inert placebo (calcium tablets)
Number of subjects: 24
Study: 30463785

Group type: EXPERIMENTAL
Intervention: Rectal washout with povidone‐iodine (RW‐PI)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Rectal washout with Ringer solution with an irrigation instrument (RW‐R)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Rectal washout with Ringer solution without an irrigation instrument (RW)
Number of subjects: 69
Study: 27088462

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training at 20 Hz
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training at 40 Hz
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 45
Study: 25414931

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22607748

Group type: EXPERIMENTAL
Intervention: Responsive feeding intervention (demonstrated five feeding interactions: hand‐washing, self‐feeding, verbal responsivity, managing refusals non‐forcefully, dietary diversity)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Responsive feeding intervention
Number of subjects: 34
Study: 21661456

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sub-tenon anaesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study: 18546051

Group type: EXPERIMENTAL
Intervention: Thighplasty
Number of subjects: 14
Study: 16569820

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 20
Study: 12972305

Group type: EXPERIMENTAL
Intervention: Normal haemoglobin group (>/=13 g/dl in males, >/=12 g/dl in females)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Anaemic group (<13 g/dl in males, <12 g/dl in females)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 350
Study: 10548200

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (0.5, 1.0, 2.0, and 4.0 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 12
Study: 8740612

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine (40 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of clonidine (150 micrograms) and lignocaine (40 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of clonidine and lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: All injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 20
Study: 1896416

Group type: EXPERIMENTAL
Intervention: Transabdominal chorionic villus sampling (TA-CVS)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Transcervical chorionic villus sampling (TC-CVS)
Number of subjects: 1194
Study: 6342863

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30790690

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (oral P2Y12 inhibitors)
Number of subjects: 136
Study: 29169907

Group type: EXPERIMENTAL
Intervention: Upside-down position
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Valsalva manoeuvre (VM)
Number of subjects: 24
Study: 28076182

Group type: EXPERIMENTAL
Intervention: Mindfulness training (Learning to BREATHE program)
Number of subjects: 109
Study: 26205277

Group type: EXPERIMENTAL
Intervention: Community mobilization and interventions to improve emergency obstetric and newborn care
Number of subjects: 33708

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33708
Study: 23946346

Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) diet (GI 70)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 65% carbohydrate (CHO) intake
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High GI diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Refeeding after CR
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 65% CHO intake during refeeding
Number of subjects: 32
Study: 21127451

Group type: EXPERIMENTAL
Intervention: Intervention group (advanced practice nurses and psychiatric consultation‐liaison nurse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group (instructions on symptom management toolkit)
Number of subjects: 0
Study: 18978630

Group type: EXPERIMENTAL
Intervention: Ballistic bench throw (BT) at 55% and 80% of predicted one-repetition maximum
Number of subjects: 8

Group type: COMPARATOR
Intervention: Traditional bench press (BP) at 55% and 80% of predicted one-repetition maximum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ballistic bench throw (BT) at 80% of predicted one-repetition maximum
Number of subjects: 8
Study: 17146153

Group type: EXPERIMENTAL
Intervention: Experimental candy containing beta‐conglycinin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo candy containing casein
Number of subjects: 240
Study: 12919177

Group type: EXPERIMENTAL
Intervention: Complementary medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11080723

Group type: EXPERIMENTAL
Intervention: 5 g of MSG
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Increasing doses of MSG
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 5 g of MSG with food
Number of subjects: 130
Study: 9192929

Group type: COMPARATOR
Intervention: General exercise training while breathing room air (GET/RA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: General exercise training while breathing supplemental oxygen (GET/O2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (GET/RA and GET/O2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Supplementation of oxygen during training
Number of subjects: 24
Study: 8445420

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) intravenously (IV), six cycles every 4 weeks
Number of subjects: 747

Group type: COMPARATOR
Intervention: Tamoxifen (Tam) 30 mg/d for 2 years
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (AC) intravenously, eight cycles every 3 weeks
Number of subjects: 747

Group type: COMPARATOR
Intervention: AC plus Tam
Number of subjects: 747
Study: 3885700

Group type: EXPERIMENTAL
Intervention: Propafenone, 300 mg every 8 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Disopyramide, 200 mg every 8 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31287336

Group type: EXPERIMENTAL
Intervention: HEART program
Number of subjects: 226

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 226
Study: 30592183

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 26905433

Group type: EXPERIMENTAL
Intervention: Dialysate calcium at 1.25 mmol/l
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dialysate calcium at 1.5 mmol/l (Control)
Number of subjects: 82
Study: 25242594

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUDs) - ever use
Number of subjects: 16858

Group type: EXPERIMENTAL
Intervention: Inert IUDs
Number of subjects: 16858

Group type: EXPERIMENTAL
Intervention: Older age at first use (≥ 35 years)
Number of subjects: 16858

Group type: EXPERIMENTAL
Intervention: Older age at last use (≥ 45 years)
Number of subjects: 16858

Group type: EXPERIMENTAL
Intervention: Longer duration of use (≥ 10 years)
Number of subjects: 16858

Group type: EXPERIMENTAL
Intervention: Recent use (within 1 year of study entry)
Number of subjects: 16858
Study: 22235139

Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg single oral dose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls (matched, n = 9)
Number of subjects: 9
Study: 19691492

Group type: EXPERIMENTAL
Intervention: Velusetrag 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Velusetrag 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Velusetrag 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18344007

Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk only as a child
Number of subjects: 22808

Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk as a child and an adult
Number of subjects: 22808

Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk only as a child (adjusted for confounding factors)
Number of subjects: 22808

Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk as a child and an adult (adjusted for confounding factors)
Number of subjects: 22808